PAREXEL's Bio/pharmaceutical R & D Statistical SourcebookPAREXEL International Corporation, 2006 - Drugs |
From inside the book
88 pages matching clinical trials in this book
Page xi
Page xiii
Where's the rest of this book?
Results 1-3 of 88
Common terms and phrases
according active analysis Annual applications approval Assessment average billion biological biotech cancer Cardiovascular Center clinical development clinical research clinical trials Cohort companies compared compounds conducted continued cost Costs/Complexity countries Date decline disease Disorders Division Drug Development enrollment estimates Europe European exhibit expected FDA First Action FDA Second Action figures filed firms five global growth Health improvement increase Indication industry International investment Japan launch leading major March mean Median medicines Merck months NCES Note Novartis oncology patients percent period Pfizer Pharma pharmaceutical Phase Phase II pipeline preclinical Priority probability projects R&D expenditure R&D spending recent regulatory reported represent Review shows Source Sponsor Response stage Standard Statistics submission Success Rates survey testing therapeutic therapeutic areas Total track treatment Tufts United